

16782

EVALUATION OF CHITIN METAL SILICATE CO PRECIPITATES
AS POTENTIAL MULTIFUNCTIONAL EXCIPIENTS IN TABLET
FORMULATIONS

By

Rana Hani Mohammed Ali Al-Shaikh Hamed

A thesis Submitted in
Partial Fulfillment of the
Requirements for the Degree of

Master of Science

at

Petra University

Faculty of pharmacy

Amman-Jordan

June 2009

Petra University Library



90339

University of Petra Library	
Accession Number :	90339
Date :	Th
Classification Number :	65-14

H212

EVALUATION OF CHITIN METAL SILICATE CO PRECIPITATES
AS POTENTIAL MULTIFUNCTIONAL EXCIPIENTS IN TABLET
FORMULATIONS

By

Rana Hani Mohammed Ali Al-Shaikh Hamed

A thesis Submitted in Partial Fulfillment of the Requirements for the Degree of

Master of Sciences

at

Petra University

Faculty of pharmacy

Amman-Jordan

June 2009

Major Supervisor

Name


Prof. Mohammed Shubair

Signature



Co- Supervisor

Dr. Faisal Al-Akayleh



Examination Committee

Name

Signature .

1. Prof. Mohammed Shubair




2. Dr. Faisal Al-Akayleh



3. Prof. Nasir Idkaidek



4. Dr. Hatim Al-Khatib



Abstract

EVALUATION OF CHITIN METAL SILICATE CO PRECIPITATES AS POTENTIAL MULTIFUNCTIONAL EXCIPIENTS IN TABLET FORMULATIONS

By

Rana Hani Mohammed Ali Al-Shaikh Hamed

Petra University, 2009

Under the supervision of Prof. Mohammed Shubair and Dr. Faisal Al- Akayleh

Three novel chitin metal silicates (CMS) were prepared namely chitin calcium silicate (CCaS), chitin magnesium silicate (CMgS), and chitin aluminum silicate (CAIS).

These CMS were tested as multifunctional direct compression and wet-granulation excipients in the design of tablets containing ibuprofen (IBU), metronidazole (MET) and spironolactone (SPL) as models of low and high dose drugs.

Commercial tablets containing these drugs and tablets made using Avicel[®] 200; one of the most commonly and widely used commercial direct compression excipient; were studied for comparison purposes.

The pH of the media of preparation of these CMS co precipitates was measured to be: 10, 9, and 4 for CCaS, CMgS, and CAIS, respectively. CAIS was selected to test the effect of altering this pH from 4 to 7 or 8 and found to highly

affect its functionality with respect to hardness, disintegration time and dissolution rate.

The friability values for all the prepared tablets were below the maximum 1% USP tolerance limit. All CMS containing formulas showed crushing strength within the acceptable range ($>40\text{N}$). For all tested drugs, the CMS (prepared at their appropriate $\text{pH}_{(s)}$, 10, 9 and 4 for CCaS, CMgS and CAIS respectively) based tablets showed outstanding disintegration characteristics (disintegration time less than 60s) for tablets prepared by direct compression or wet granulation methods. The type of CMS was found not to affect the disintegration time and crushing strength of the tablets. Regarding the dissolution profiles, CMS tablets demonstrate superiority over the Avicel[®] 200 based tablets except for those with metronidazole which showed similar dissolution profile. In addition, they demonstrate faster dissolution profiles than Fleximex[®] and Dumazole[®] but slower than Aldactone[®].

Compressional properties of formulations were analyzed using density measurements and the compression equations of Heckel and Kawakita as assessment parameters. CMgS was selected as an example. All tested formulas gave plots with an initial curved region followed by a linear portion, which is typical of B-type materials; this indicates that the materials first underwent fragmentation, followed by plastic deformation. Formulas containing CMgS with ibuprofen, metronidazole or spironolactone showed lower yield values (P_y) than CMgS alone which indicate faster onset and higher amount of plastic deformation. A linear relationship was found to exist between P/C (applied pressure/degree of volume reduction) and P (pressure) for all tested formulations (CMgS alone and CMgS with ibuprofen, metronidazole or spironolactone). The value of " $1/b$ "; which represents the cohesive properties of powders, for CMgS alone is higher than those with drugs. The lower value of " $1/b$ " of

CMgS in the presence of drugs is indicative of the reduction in cohesive forces. In other words, the presence of drugs increased the plastic deformation of CMgS under pressure. These results are in positive correlation with Heckel parameter (Py).

Differential scanning calorimetry (DSC) was used as a screening technique for assessing the compatibility of the model drugs with CMS employed in tablet formulations. On the basis of DSC results, CMS co precipitates were found to be chemically compatible with the tested drugs.

These results conclusively show that the prepared CMS co precipitates have the potential to be used as filler, binder, and disintegrant, all-in-one, in the design of tablets containing either a low or high dose drug by direct compression and wet-granulation methods.


Major Supervisor Signature

Prof. Mohammed Shubair



Co- Supervisor Signature

Dr. Faisal Al- Akayleh



To
My Family.....

ACKNOWLEDGMENTS

I would like to express my deep and sincere gratitude to my supervisor, Professor Mohammed Shubair, Ph.D., chairman, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy and Medical Sciences, Petra University. His wide knowledge and his logical way of thinking have been of great value for me. His understanding, encouraging and personal guidance have provided a good basis for the present thesis.

I am deeply grateful to my co-supervisor, Assistant Professor Dr. Faisal Al-Akayleh, Ph.D., Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy and Medical Sciences, Petra University, for supervising this work, for his detailed and constructive comments, for his important support throughout this work and for giving me the chance to join his research group.

I owe my warm sincere gratitude to Dr. Adnan Badwan, Ph.D, General Director of Jordanian Pharmaceutical Manufacturing Co., JPM, who gave me the opportunity to work with them in JPM Co., and gave me untiring help during my difficult moments.

I warmly thank Dr. Iyad Rashid, Ph.D., and Dr. Mayyas Al-Remawi, Ph.D (JPM Co.) , for their valuable advice and friendly help. Their extensive discussions around my work and interesting explorations in operations have been very helpful for this study.

During this work I have collaborated with many colleagues for whom I have great regard, and I wish to extend my warmest thanks to all those who have helped me with my work in the Faculty of Pharmacy and Medical Sciences at Petra University in Amman, Jordan.

I owe my loving thanks to my Husband Mohammed, my son Omar. They have lost a lot due to my research abroad. Without their encouragement and understanding it would have been impossible for me to finish this work. My special gratitude is due to my father Hani and mother Nawal and to my brother, my sisters for their loving support.

I am grateful to my mother and my husband for encouraging me to come to Jordan to do my studies.

The overall support of Petra University is gratefully acknowledged.

Rana, Jordan, June 2009

Rana Hani Mohammed Ali Al-Shaikh Hamed

Table of Contents

Contents	Page
TITLE PAGE	I
ABSTRACT	III
DEDICATION	VI
ACKNOWLEDGEMENTS	VII
TABLE OF CONTENT	IX
LIST OF FIGURES	XII
LIST OF TABLES	XV
ABBREVIATIONS	XVII
Chapter One: Introduction	
No.	Page
1	2
1.1	2
1.2	2
1.2.1	3
1.2.2	4
1.2.3	7
1.2.3.1	7
1.2.3.2	9
1.2.3.3	10
1.2.3.4	11
1.2.4	16
1.3	18
1.3.1	18
1.3.2	20
1.3.3	21
1.4	24
1.4.1	24
1.4.1.1	25
1.5	29
1.6	32
1.6.1	32
1.6.2	32
1.6.3	33
1.7	34

Contents		Page
Chapter Two: Experimental		
No.		Page
2	Materials and Methods	37
2.1	Materials	37
2.2	Methods	38
2.2.1	Preparation of Chitin- Ca, -Mg and -Al Silicate Co precipitates	38
2.2.2	Preparation of Chitin Al Silicate Co precipitates of pH7 and pH8	39
2.2.3	Preparation of Tablets by Direct Compression Method	39
2.2.4	Preparation of Tablets by Wet Granulation Method using Chitin Mg Silicate	39
2.2.5	Measurement of Tablets Friability	40
2.2.6	Measurement of Tablets Hardness and Thickness	42
2.2.7	Disintegration Test	42
2.2.8	Dissolution Test	42
2.3	Calibration Curves of Model Drugs	43
2.3.1	Calibration Curve of Ibuprofen	43
2.3.2	Calibration Curve of Metronidazole	43
2.3.3	Calibration Curve of Spironolactone	44
2.4	Tablets Compressibility Studies	44
2.4.1	Heckel Plot	44
2.4.2	Kawakita Plot	45
2.5	Differential Scanning Calorimetry (DSC) Study	46
2.6	Statistical Analysis	46
Chapter Three: Results and Discussion		
No.		Page
3	Results and Discussion	48
3.1	Preparation and Characterization of Tablets using a Single Tablet Excipient	48
3.1.1	Hardness , Thickness and Friability Studies	48
3.1.1.1	Effect of Excipient Type on Crushing Strength	50
3.1.1.2	Effect of the Method of Addition of Chitin Mg Silicate on the Crushing Strength	51
3.1.1.3	Effect of pH of the preparation media of Chitin Al Silicate on Crushing Strength	52

Contents		Page
3.1.1.4	Effect of different Drug / Chitin Metal Silicate Ratio on Crushing Strength	53
3.1.2	Disintegration Studies	54
3.1.2.1	Effect of Chitin Metal Silicate Type on Disintegration Time	54
3.1.2.2	Effect of the Method of Addition of Chitin Metal Silicate on Disintegration time	54
3.1.2.3	Effect of pH of the preparation media of Chitin Al Silicate on Disintegration time	54
3.1.2.4	Comparative Disintegration Time with commercial products and Avicel® 200 containing formulas	55
3.1.3	Calibration Curves of Model Drugs	57
3.1.4	Dissolution Studies	59
3.1.4.1	Effect of Chitin Metal Silicate Type on Drug Dissolution	59
3.1.4.2	Comparative Dissolution Profile Studies	61
3.1.4.3	Effect of pH of the preparation media of Chitin Metal Silicate on Drug Dissolution	64
3.1.4.4	Effect of different Drug / Chitin Metal Silicate Ratio on Drug Dissolution	65
3.1.4.5	Effect of the Method of Addition of Chitin Metal Silicate on Drug Dissolution	66
3.2	Compressibility Studies	68
3.2.1	Heckel Plot Results	68
3.2.2	Kawakita Plot Results	71
3.3	Compatibility Study	74
3.3.1	Differential Scanning Calorimetry (DSC)	74
Chapter Four: Conclusions		
4	Conclusions	82
Appendix		
References		

List of Figures

Figure No.		Page No.
Chapter One: Introduction		
1.1	Structure of cellulose	14
1.2	Structure of chitin	19
1.3	Structure of chitosan	19
1.4	Structure of ibuprofen	32
1.5	Structure of Metronidazole	32
1.6	Structure of spironolactone	33
Chapter Three: Results and Discussion		
3.1	Effect of Drug/CMS ratio on crushing strength	53
3.2	Disintegration test for ibuprofen tablets containing CCaS (chitin Ca silicate), CMgS (chitin Mg silicate), CAIS (chitin Al silicate), Avicel [®] 200 as fillers, and commercial product.	56
3.3	Disintegration test for metronidazole tablets containing CCaS (chitin Ca silicate), CMgS (chitin Mg silicate), CAIS (chitin Al silicate), Avicel [®] 200 as fillers, and commercial product.	56
3.4	Disintegration test for spironolactone tablets containing CCaS (chitin Ca silicate), CMgS (chitin Mg silicate), CAIS (chitin Al silicate), Avicel [®] 200 as fillers, and commercial product.	57
3.5	Calibration curve of ibuprofen.	57
3.6	Calibration curve of metronidazole.	58
3.7	Calibration curve of spironolactone.	58
3.8	Dissolution profile of ibuprofen released from Formula ID1 (chitin Ca silicate), Formula ID2 (chitin Mg silicate) and Formula ID5 (chitin Al silicate).	59
3.9	Dissolution profile of metronidazole released from Formula MD1 (chitin Ca silicate), Formula MD2 (chitin Mg silicate) and Formula MD3 (chitin Al silicate).	60
3.10	Dissolution profile of spironolactone released from Formula SD1 (chitin Ca silicate), Formula SD4 (chitin Mg silicate) and Formula SD10 (chitin Al silicate).	61
3.11	Dissolution profile ibuprofen of Formula ID1 (chitin Ca silicate), Formula I Avicel (Avicel [®] 200) as fillers, and commercial product.	62

Figure No.		Page No.
3.12	Dissolution profile metronidazole of Formula MD1 (chitin Ca silicate), Formula M Avicel (Avicel® 200) as fillers, and commercial product.	62
3.13	Dissolution profile spironolactone of Formula SD1 (chitin Ca silicate), Formula S Avicel (Avicel® 200) as fillers, and commercial product.	63
3.14	Dissolution profile ibuprofen of Formula ID4 (chitin Al silicate pH 7) and ID5 (chitin Al silicate pH 4).	64
3.15	Dissolution profile spironolactone of Formula SD8 (chitin Al silicate pH 8), SD9 (chitin Al silicate pH 7) and SD10 (chitin Al silicate pH 4).	65
3.16	Dissolution profile spironolactone from Formulas of different drug/chitin Mg silicate ratio; SD4 (1/11), Formula SD6 (1/4) and SD7 (1/1).	66
3.17	Dissolution profile of ibuprofen with chitin Mg silicate Formula ID2 (direct compression), Formula III (wet intra- granulation) and IE1 (wet extra-granulation).	66
3.18	Dissolution profile of metronidazole with chitin Mg silicate Formula MD2 (direct compression), Formula MI2 (wet intra-granulation) and ME2 (wet extra-granulation).	67
3.19	Heckel plot of chitin Mg silicate.	68
3.20	Heckel plot of formula ID2 (400mg ibuprofen with 300mg chitin Mg silicate).	69
3.21	Heckel plot of formula MD2 (500mg metronidazole with 300mg chitin Mg silicate).	69
3.22	Heckel plot of formula SD4 (25mg spironolactone with 275mg chitin Mg silicate).	70
3.23	Kawakita plot of chitin Mg silicate.	72
3.24	Kawakita plot of formula ID2 (400mg ibuprofen with 300mg chitin Mg silicate).	72
3.25	Kawakita plot of formula MD2 (500mg metronidazole with 300mg chitin Mg silicate).	73
3.26	Kawakita plot of formula SD4 (25mg spironolactone with 275mg chitin Mg silicate).	73
3.27	DSC of chitin Ca silicate, chitin Mg silicate and chitin Al silicate.	75

Figure		Page
No.		No.
3.28	Comparison between ibuprofen alone and ibuprofen with chitin calcium silicate (CCaS).	75
3.29	Comparison between ibuprofen alone and ibuprofen with chitin magnesium silicate (CMgS).	76
3.30	Comparison between ibuprofen alone and ibuprofen with chitin aluminum silicate (CAIS).	76
3.31	Comparison between metronidazole alone and metronidazole with chitin calcium silicate (CCaS).	77
3.32	Comparison between metronidazole alone and metronidazole with chitin magnesium silicate (CMgS).	77
3.33	Comparison between metronidazole alone and metronidazole with chitin aluminum silicate (CAIS).	78
3.34	Comparison between spironolactone alone and spironolactone with chitin calcium silicate (CCaS).	78
3.35	Comparison between spironolactone alone and spironolactone with chitin magnesium silicate (CMgS).	79
3.36	Comparison between spironolactone alone and spironolactone with chitin aluminum silicate (CAIS).	79

List of Tables

Table No.		Page No.
Chapter Two: Experimental		
2.1	Tablets compositions, weight, punch size used and formula number.	41
2.2	Dissolution conditions used for IBU, MET and SPI tablets.	43
2.3	Weight of each formula used to measure true density	44
Chapter Three: Results and Discussion		
3.1	Hardness, friability and disintegration time of the commercial as well as the formulated tablets.	49
3.2	Effect of the type of chitin metal silicate on crushing strength.	50
3.3	Effect of wet granulation method on crushing strength using chitin Mg silicate.	51
3.4	Effect of pH of chitin Al silicate on crushing strength.	52
3.5	Disintegration times of tablets containing chitin Al silicate prepared in different media of preparation.	55
3.6	Parameters obtained from Heckel plots for Formulas ID2, Formula MD2, Formula SD4, and chitin Mg silicate alone.	70
3.7	Parameters obtained from Kawakita plots for Formulas ID2, Formula MD2, Formula SD4, and chitin Mg silicate alone.	74
Appendix		
A 3.1	% Released of ibuprofen from Formula ID1, Formula ID2 and Formula ID5 which represent the three types of CMS; chitin Ca silicate, chitin Mg silicate and chitin Al silicate respectively.	84
A 3.2	% Released of metronidazole from Formula MD1, Formula MD2 and Formula MD3 which represent the three types of CMS; chitin Ca silicate, chitin Mg silicate and chitin Al silicate respectively.	84
A 3.3	% Released of spironolactone from Formula SD1, Formula SD4 and Formula SD10 which represent the three types of CMS; chitin Ca silicate, chitin Mg silicate and chitin Al silicate respectively.	85
A 3.4	% Released of ibuprofen of Formula ID1 (chitin Ca silicate), Formula I Avicel (Avicel [®] 200) as fillers, and commercial product.	85

Figure No.		Page No.
A 3.5	% Released of metronidazole of Formula MD1 (chitin Ca silicate), Formula M Avicel (Avicel [®] 200) as fillers, and commercial product.	86
A 3.6	% Released of spironolactone of Formula MD1 (chitin Ca silicate), Formula S Avicel (Avicel [®] 200) as fillers, and commercial product.	86
A 3.7	% Released of ibuprofen of Formula ID4 (chitin Al silicate pH 7) and ID5 (chitin Al silicate pH 4).	87
A 3.8	% Released of spironolactone of Formula SD8 (chitin Al silicate pH 8), Formula SD9 (chitin Al silicate pH 7) and SD10 (chitin Al silicate pH 4).	87
A 3.9	% Released of spironolactone of Formulas of different drug/chitin Mg silicate ratio SD4 (1/11), Formula SD6 (1/4) and SD7 (1/1).	88
A 3.10	% Released of ibuprofen from Formulas contains ibuprofen with chitin Mg silicate prepared in different method, Formula ID2 (direct compression) Formula III (wet intra- granulation) and IE1 (wet extra-granulation).	88
A 3.11	% Released of metronidazole from Formulas contains metronidazole with chitin Mg silicate prepared in different method, Formula MD2 (direct compression) Formula MI2 (wet intra- granulation) and ME2 (wet extra-granulation).	89
A 3.12	Heckel plot calculations chitin Mg silicate.	89
A 3.13	Heckel plot calculations of formula ID2 (400mg ibuprofen with 300mg chitin Mg silicate).	90
A 3.14	Heckel plot calculations of formula MD2 (500mg metronidazole with 300mg chitin Mg silicate).	90
A 3.15	Heckel plot calculations of formula SD4 (25mg spironolactone with 300mg chitin Mg silicate).	91
A 3.16	Heckel plot calculations of ibuprofen.	91
A 3.17	Kawakita plot calculations of chitin Mg silicate.	92
A 3.18	Kawakita plot calculations of formula ID2 (400mg ibuprofen with 300mg chitin Mg silicate).	92
A 3.19	Kawakita plot calculations of formula MD2 (500mg metronidazole with 300mg chitin Mg silicate).	93
A 3.20	Kawakita plot calculations of formula SD4 (25mg spironolactone with 300mg chitin Mg silicate).	93

Abbreviations

CMS	Chitin Metal Silicates
CCaS	Chitin Calcium Silicate
CMgS	Chitin Magnesium Silicate
CAIS	Chitin Aluminum Silicate
MFE	Multi-Functional Excipient
DSC	Differential Scanning Calorimetry
IBU	Ibuprofen
MET	Metronidazole
SPL	Spironolactone

Chapter 1

Introduction

Chapter 1

1. Introduction

1.1 Solid Dosage Form

A pharmaceutical dosage form is a preparation designed to make possible the administration of drug in measured or prescribed amounts, such as a tablet, capsule or injection. The route of administration is dependent on the dosage form of a given drug (Allen *et al*, 2005; Gad, 2008).

Solid dosage form is one of the most popular pharmaceutical dosage forms contain active and inactive ingredient(s), in which the drug present as prescribed amount, so it is more accurate, stable and easier to administer to patient, i.e. it is more convenient for administration (Medina and Kumar, 2006).

1.2 Pharmaceutical Tablets

Because oral administration of drugs is simple, convenient and safe, it is the most frequently used route. At least 90% of all drugs used to produce systemic effects are administered orally (Gohel *et al*, 2007a).

The European Pharmacopoeia (2002) defines tablets as solid preparations each containing a single dose of one or more active substances and usually obtained by compressing uniform volumes of particles. Tablets are intended for oral administration. Some are swallowed whole, some after being chewed, some are dissolved or dispersed in water before being administered and some are retained in the mouth where the active substance is liberated. Despite the long and continuing history of the development of new technologies for administration of drugs, the tablet form remains the most commonly used dosage form (Eup. P., 2002).

In addition, tablets are considered to be one of the most preferred dosage forms because of their ease of manufacturing, convenience in administration, accurate dosing and stability compared with oral liquids, and because they are more tamperproof than capsules. So their popularity is continuously increasing day by day (Lund, 1994; Winfield and Richards, 2004).

1.2.1 Classification of Tablets

Based on their drug-release characteristics, tablets can be classified into:

a- Immediate Release Tablets

In immediate release tablets the drug is intended to be released rapidly after administration, or the tablet is dissolved and administered as a solution. This is the most common type of tablets and includes: disintegrating, chewable, effervescent, lozenges, sublingual and buccal tablets (Goran, 2002).

b- Modified-Release Tablets

In contrast to conventional tablets or tablets for instant release, modified release tablets can provide a range of release patterns (extended, delayed or repeated release) resulting in deposition of the drug in varying positions within the gastrointestinal tract.

Several alternative terms are used to describe extended release systems, such as controlled release, prolonged release and sustained release. The release rate and/or time to release onset differ among the modified release tablet systems, but the main common objective is to control the release of the drug from the dosage form. The main mechanisms that can be controlled are the dissolution of the active substance and the diffusion of the dissolved drug within the tablet. There are several techniques available to accomplish this. A dissolution controlled release system can be obtained by covering the readily soluble drug particles and / or the tablets with slowly soluble

coatings. It is also possible to modify the structure of the active substance to reduce its solubility, resulting in a slower dissolution rate. The diffusion can be controlled by the addition of an insoluble membrane surrounding the drug particles or the tablets or by forming matrix tablets. In the latter, the active substance dissolves within the tablet and diffuses through the membrane or matrix. The drug can also be incorporated into an eroding matrix; the drug is then released as the matrix erodes and also by a diffusion process within the matrix (John and Chris, 2002).

1.2.2 Tablet Excipients

In tablet formulation, a range of excipient materials is normally required along with the active ingredient in order to give the tablet the desired properties. For example, the reproducibility and dose homogeneity of the tablets are dependent on the properties of the powder mass. The tablet should also be sufficiently strong to withstand handling, but should disintegrate after intake to facilitate drug release. The choice of excipients will affect all these properties (Goran, 2002). These pharmaceutically inactive ingredients include:

Diluents or fillers: which fill out the size of a tablet or capsule, making it practical to produce and convenient for the consumer to use by increasing the bulk volume of the formulation, the final product has the proper volume for patient handling. A good filler must be inert, compatible with the other components of the formulation, non-hygroscopic, soluble, relatively cheap, compactable, and preferably tasteless or pleasant tasting (as in chewable tablet). Examples of diluents are lactose, dicalcium phosphate dihydrate, sucrose, glucose, mannitol, sorbitol, calcium sulphate and others (Lachman *et al*, 1986).

Binder: A material with a high bonding ability can be used as a binder to increase the mechanical strength of the tablet. A binder is usually a ductile material